REPROS THERAPEUTICS INC.

Form 3

October 26, 2007

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB

2005

0.5

3235-0104 Number: January 31, Expires:

OMB APPROVAL

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, response... Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Efficacy Capital, Ltd.	2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol REPROS THERAPEUTICS INC. [RPRX]				
(Last) (First) (Middle	10/16/2007	10/16/2007 4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)		
11622 EI CAMINO REAL, SUITE 100		(Check a	ll applicable)			
(Street)		Director Officer (give title below)	_X10% Other (specify belo		6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting	
SAN DIEGO, CA 92130					Person _X_ Form filed by More than One Reporting Person	
(City) (State) (Zip)	Table I - N	Non-Derivativ	e Securiti	es Bei	neficially Owned	
1.Title of Security (Instr. 4)	2. Amount o Beneficially (Instr. 4)	Owned I	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	•	
Common Stock	1,680,413		I	By in	nvestment funds (1)	
Reminder: Report on a separate line for owned directly or indirectly.	or each class of securities benefic	ially SE	C 1473 (7-02)		
information c	respond to the collection of ontained in this form are not spond unless the form displ					

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

currently valid OMB control number.

	1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title	Security	Direct (D)		

Edgar Filing: REPROS THERAPEUTICS INC. - Form 3

Date Expiration Amount or or Indirect
Exercisable Date Number of (I)
Shares (Instr. 5)

Reporting Owners

Reporting Owner Name / Address	Relationships						
coporting of more remained	Director	10% Owner	Officer	Othe			
Efficacy Capital, Ltd. 11622 EI CAMINO REAL SUITE 100 SAN DIEGO, CA 92130	Â	ÂX	Â	Â			
Lappe Mark 11622 EI CAMINO REAL SUITE 100 SAN DIEGO, CA 92130	Â	ÂΧ	Â	Â			
Kayyem Jon Faiz 11622 EI CAMINO REAL SUITE 100 SAN DIEGO, CA 92130	Â	ÂΧ	Â	Â			
Efficacy Biotech Master Fund Ltd. 11622 EI CAMINO REAL SUITE 100 SAN DIEGO, CA 92130	Â	ÂX	Â	Â			

Signatures

Mark Lappe, Managing
Partner
10/26/2007

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Includes 1,533,013 shares held by Efficacy Biotech Master Fund Ltd., a Bermuda Exempted Mutual Fund Company ("EBMFL") and

(1) 147,400 shares held by FMG Special Situations Fund. The Reporting Company acts as an investment advisor with investment and voting discretion over portfolio investments. The Reporting Company is an indirect beneficial owner of the reported securities.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2